Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
25.7
USD
|
+0.23%
|
|
-2.58%
|
+26.85%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,098
|
705.1
|
719.4
|
866.2
|
1,329
|
-
|
-
|
Enterprise Value (EV)
1 |
821.4
|
457.3
|
505.9
|
617.1
|
826.8
|
925.3
|
1,129
|
P/E ratio
|
-4.7
x
|
-8.54
x
|
-6.69
x
|
-7.85
x
|
-8.4
x
|
-8.53
x
|
-7.8
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
80.7
x
|
39.1
x
|
230
x
|
41.8
x
|
188
x
|
157
x
|
197
x
|
EV / Revenue
|
60.3
x
|
25.4
x
|
162
x
|
29.8
x
|
117
x
|
109
x
|
167
x
|
EV / EBITDA
|
-14.9
x
|
-6.55
x
|
-4.7
x
|
-5.68
x
|
-5.33
x
|
-4.03
x
|
-3.93
x
|
EV / FCF
|
-15.8
x
|
-
|
-5.15
x
|
-7.85
x
|
-4.89
x
|
-5.44
x
|
-6.12
x
|
FCF Yield
|
-6.32%
|
-
|
-19.4%
|
-12.7%
|
-20.4%
|
-18.4%
|
-16.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
26,494
|
32,139
|
32,392
|
42,754
|
51,703
|
-
|
-
|
Reference price
2 |
41.45
|
21.94
|
22.21
|
20.26
|
25.70
|
25.70
|
25.70
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
13.61
|
18.04
|
3.129
|
20.72
|
7.086
|
8.458
|
6.746
|
EBITDA
1 |
-55.22
|
-69.81
|
-107.6
|
-108.7
|
-155.2
|
-229.8
|
-287.1
|
EBIT
1 |
-56.66
|
-71.33
|
-110
|
-112.9
|
-157.4
|
-199.7
|
-231.4
|
Operating Margin
|
-416.28%
|
-395.46%
|
-3,516.52%
|
-544.65%
|
-2,221.54%
|
-2,361.07%
|
-3,430.47%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-107.5
|
-100.8
|
-147.7
|
-136.3
|
-199.6
|
Net income
1 |
-56.69
|
-71.32
|
-107.5
|
-100.8
|
-150.4
|
-165.8
|
-199.6
|
Net margin
|
-416.49%
|
-395.37%
|
-3,435.41%
|
-486.59%
|
-2,122.57%
|
-1,960.55%
|
-2,958.41%
|
EPS
2 |
-8.820
|
-2.570
|
-3.320
|
-2.580
|
-3.058
|
-3.014
|
-3.293
|
Free Cash Flow
1 |
-51.91
|
-
|
-98.22
|
-78.56
|
-169
|
-170.1
|
-184.3
|
FCF margin
|
-381.35%
|
-
|
-3,139.05%
|
-379.11%
|
-2,384.62%
|
-2,011.47%
|
-2,732.36%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.092
|
1.219
|
0.162
|
0.5
|
1.247
|
0.298
|
0.239
|
20.2
|
-0.019
|
-
|
1.207
|
1.212
|
1.218
|
0.5
|
0.5
|
EBITDA
|
-24.37
|
-
|
-27.96
|
-
|
-
|
-29.08
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-24.76
|
-26.39
|
-28.43
|
-26.5
|
-28.72
|
-30.11
|
-32.14
|
-13.97
|
-36.65
|
-38.14
|
-38.8
|
-39.5
|
-41.2
|
-46
|
-50
|
Operating Margin
|
-26,917.39%
|
-2,165.05%
|
-17,546.91%
|
-5,299%
|
-2,303.13%
|
-10,102.68%
|
-13,446.03%
|
-69.16%
|
192,905.26%
|
-
|
-3,214.05%
|
-3,258%
|
-3,381.48%
|
-9,200%
|
-10,000%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-28.09
|
-25.69
|
-27.38
|
-28.68
|
-29.62
|
-10.26
|
-32.28
|
-32.4
|
-36.13
|
-37.46
|
-39.82
|
-
|
-
|
Net income
1 |
-25.08
|
-26.34
|
-28.09
|
-25.69
|
-27.38
|
-28.68
|
-29.62
|
-10.26
|
-32.28
|
-32.4
|
-38.4
|
-38.4
|
-44.3
|
-
|
-
|
Net margin
|
-27,264.13%
|
-2,160.62%
|
-17,337.04%
|
-5,138.2%
|
-2,195.59%
|
-9,624.83%
|
-12,391.63%
|
-50.76%
|
169,910.53%
|
-
|
-3,180.91%
|
-3,167.27%
|
-3,635.92%
|
-
|
-
|
EPS
2 |
-0.8500
|
-0.8200
|
-0.8700
|
-0.7900
|
-0.8400
|
-0.8800
|
-0.7700
|
-0.2400
|
-0.7700
|
-0.6600
|
-0.7725
|
-0.8100
|
-0.8500
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/28/22
|
5/12/22
|
8/11/22
|
11/8/22
|
3/15/23
|
5/10/23
|
8/9/23
|
11/9/23
|
2/29/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
277
|
248
|
214
|
249
|
502
|
403
|
200
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-51.9
|
-
|
-98.2
|
-78.6
|
-169
|
-170
|
-184
|
ROE (net income / shareholders' equity)
|
-61.8%
|
-24.8%
|
-39.1%
|
-37.4%
|
-44.6%
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
2 |
-7.920
|
-2.490
|
-2.680
|
-1.940
|
-
|
-
|
-
|
Capex
1 |
1
|
-
|
11.5
|
2.77
|
10
|
7.27
|
4.79
|
Capex / Sales
|
7.35%
|
-
|
368.68%
|
13.37%
|
141.13%
|
85.91%
|
70.99%
|
Announcement Date
|
3/25/21
|
3/28/22
|
3/15/23
|
2/29/24
|
-
|
-
|
-
|
Last Close Price
25.7
USD Average target price
52.3
USD Spread / Average Target +103.50% Consensus |
1st Jan change
|
Capi.
|
---|
| +26.85% | 1.33B | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|